374 related articles for article (PubMed ID: 34479924)
1. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL; Bluestone JA; Bucktrout S; Butterfield LH; Jaffee EM; Koch CA; Roep BO; Sharpe AH; Murphy WJ; Villani AC; Walunas TL
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479924
[TBL] [Abstract][Full Text] [Related]
2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
3. Strategies for improving the management of immune-related adverse events.
Naing A; Hajjar J; Gulley JL; Atkins MB; Ciliberto G; Meric-Bernstam F; Hwu P
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33310772
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
5. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
6. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
7. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
8. Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors.
Fiala O; Sorejs O; Sustr J; Kucera R; Topolcan O; Finek J
Anticancer Res; 2020 Mar; 40(3):1219-1227. PubMed ID: 32132018
[TBL] [Abstract][Full Text] [Related]
9. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
10. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon AC; Burton LB; Chwalisz BK; Hillis J; Schaller TH; Amato AA; Betof Warner A; Brastianos PK; Cho TA; Clardy SL; Cohen JV; Dietrich J; Dougan M; Doughty CT; Dubey D; Gelfand JM; Guptill JT; Johnson DB; Juel VC; Kadish R; Kolb N; LeBoeuf NR; Linnoila J; Mammen AL; Martinez-Lage M; Mooradian MJ; Naidoo J; Neilan TG; Reardon DA; Rubin KM; Santomasso BD; Sullivan RJ; Wang N; Woodman K; Zubiri L; Louv WC; Reynolds KL
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281989
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Stephen B; Hajjar J; Sarda S; Duose DY; Conroy JM; Morrison C; Alshawa A; Xu M; Zarifa A; Patel SP; Yuan Y; Kwiatkowski E; Wang L; Rodon Ahnert J; Fu S; Meric-Bernstam F; Lowman GM; Looney T; Naing A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604642
[TBL] [Abstract][Full Text] [Related]
12. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service.
Abu-Shawer O; Singh P; Yenulevich E; Brito A; Ni J; Abdulnour RE; Grover S; Manos M; Bowling P; LeBoeuf NR; Ott P; Stephen Hodi F; Jacobson J; Rahma O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817360
[TBL] [Abstract][Full Text] [Related]
13. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
14. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
17. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
19. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
Trinh S; Le A; Gowani S; La-Beck NM
Asia Pac J Oncol Nurs; 2019; 6(2):154-160. PubMed ID: 30931360
[TBL] [Abstract][Full Text] [Related]
20. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
Mangan BL; McAlister RK; Balko JM; Johnson DB; Moslehi JJ; Gibson A; Phillips EJ
Br J Clin Pharmacol; 2020 Sep; 86(9):1778-1789. PubMed ID: 32543711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]